Table 1.
Diabetes and non-diabetes trials evaluating aspirin for primary prevention.
| Author (Year) Trial | Study Period | No. of Patients | Male (%) | Age (yrs) | Diabetes (%) | Aspirin Dose/Day | Outcomes in RR or HR | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Myocardial Infarction | Stroke | CV Mortality | All-Cause Mortality | |||||||
| Non-diabetes | ||||||||||
| Peto R (1988) [20] | 1978–1984 | 5139 | 100 | 61 | 2 | 500 mg | NR | NR | NR | NR |
| Ongoing Physician Health Study (1989) [21] | 1982–1988 | 22,071 | NR | NR | 2 | 325 mg | RR = 0.56 (0.45–0.70) | RR = 1.22 (0.93–1.60) | RR = 0.96 (0.60–1.54) | RR = 0.96 (0.80–1.14) |
| Hansson (1998) HOT trial [22] | 1992–1997 | 18,790 | 53 | 61 | 8 | 75 mg | RR = 0.85 (0.69–1.05) | RR = 0.98 (0.78–1.24) | RR = 0.95 (0.75–1.20) | RR = 0.93 (0.79–1.09) |
| Thrombosis prevention trial (1998) [23] | 1984–1997 | 5499 | 100 | 57 | 2 | 75 mg | RR = 0.80 (0.64–0.99) | RR = 0.98 (0.65–1.47) | RR = 1.26 (0.93–1.69) | RR = 1.03 (0.80–1.32) |
| Primary prevention project (2001) [24] | 1994–1998 | 4495 | 42 | 64 | 17 | 100 mg | RR = 0.69 (0.38–1.23) | RR = 0.67 (0.36–1.27) | RR = 0.56 (0.31–0.99) | RR = 0.81 (0.58–1.13) |
| Ridker P (2005) Women’s health study [25] | 1992–2004 | 39,876 | 0 | 54 | 3 | 100 mg | RR = 1.02 (0.84–1.25) | RR = 0.83 (0.69–0.99) | RR = 0.95 (0.74–1.22) | RR = 0.95 (0.85–1.06) |
| Fowkes (2010) Aspirin for Asymptomatic Atherosclerosis trial [26] | 1998–2008 | 3350 | 28 | 62 | 3 | 100 mg | NR | NR | NR | HR = 0.95 (0.77–1.16) |
| Ikeda Y (2014) Japanese Primary Prevention Project (JPPP) [27] | 2002–2008 | 2539 | 55 | 65 | 34 | 100 mg | HR = 0.53 (0.31–0.91) | HR = 1.04 (0.80–1.34) | HR = 1.03 (0.71–1.48) | HR = 0.99 (0.85–1.17) |
| Gaziano (2018) ARRIVE [7] | 2007–2016 | 12,546 | 70 | 64 | 0 | 100 mg | HR = 0.85 (0.64–1.11) | 1.12 (0.80–1.55) | HR = 0.97 (0.62–1.52) | HR = 0.99 (0.80–1.24) |
| McNeil (2018) ASPREE [9] | 2010–2014 | 19,114 | 44 | 74 | 11 | 100 mg | HR = 0.93 (0.76–1.15) | HR = 0.95 (0.83–1.08) | NR | NR |
| Diabetes | ||||||||||
| Ogawa (2008) Japanese Primary Prevention of Atherosclerosis with Aspirin for diabetes [28] | 2002–2008 | 2539 | 55 | 65 | 100 | 81 or 100 mg | NR | HR = 0.84 (0.53–1.32) | NR | NR |
| Belch (2008) Prevention of progression of arterial disease and diabetes (POPADAD) [29] | 1997–2006 | 1276 | 44 | 60 | 100 | 100 mg | HR = 0.98 (0.68–1.43) | HR = 0.71 (0.44–1.14) | HR = 1.35 (0.81–2.25) | HR = 0.93 (0.71–1.24) |
| ASCEND (2018) [8] | 2005–2017 | 15,480 | 63 | 63 | 100 | 100 mg | HR = 0.98 (0.80–1.19) | 0.88 (0.73–1.06) | NR | NR |
Abbreviations—HR: hazard ratio, NR: not reported, RR: risk ratio.